Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Harmony Biosciences Holdings (HRMY) EBITDA (2019 - 2025)

Historic EBITDA for Harmony Biosciences Holdings (HRMY) over the last 7 years, with Q3 2025 value amounting to $51.0 million.

  • Harmony Biosciences Holdings' EBITDA rose 887.75% to $51.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $185.5 million, marking a year-over-year increase of 5005.99%. This contributed to the annual value of $145.6 million for FY2024, which is 1282.96% up from last year.
  • According to the latest figures from Q3 2025, Harmony Biosciences Holdings' EBITDA is $51.0 million, which was up 887.75% from $39.8 million recorded in Q2 2025.
  • Harmony Biosciences Holdings' EBITDA's 5-year high stood at $87.8 million during Q3 2022, with a 5-year trough of -$9.6 million in Q3 2021.
  • In the last 5 years, Harmony Biosciences Holdings' EBITDA had a median value of $33.8 million in 2023 and averaged $33.4 million.
  • Per our database at Business Quant, Harmony Biosciences Holdings' EBITDA crashed by 19267.82% in 2021 and then soared by 101261.95% in 2022.
  • Quarter analysis of 5 years shows Harmony Biosciences Holdings' EBITDA stood at $22.7 million in 2021, then soared by 113.68% to $48.5 million in 2022, then crashed by 44.11% to $27.1 million in 2023, then skyrocketed by 80.8% to $49.0 million in 2024, then rose by 3.96% to $51.0 million in 2025.
  • Its EBITDA stands at $51.0 million for Q3 2025, versus $39.8 million for Q2 2025 and $45.7 million for Q1 2025.